Event Date/Time: Sep 15, 2008
The infectious disease market is projected to grow by 3 billion dollars over the next two years, reaching 25.5 billion dollars in sales by 2011. As the instances of drug resistance and hospital-acquired infections increases globally, bio/pharmaceutical companies are faced with both unprecedented opportunities and challenges to develop products to support this every growing market. There are currently almost 400 medicines in development for infectious diseases, the majority of those being vaccines. However, despite the large number of drugs in the pipeline, experts agree that â€œthe late stage antibacterial pipeline is not keeping up with the increasing need for novel agents to target drug-resistant bacteriaâ€ (PharmaVoice, February 2008)
CBIâ€™s summit provides commercialization leaders with the tools they need to bring product to market in this very complex and rapidly changing marketplace. Industry experts highlight market opportunities and drivers, the potential of TAs, the regulatory landscape, reimbursement strategies and the impact HAIs. In addition, you walk away with a concrete tool kit on pre-launch strategies for anti-infectives.